EAM
AMBI

Eventide Asset Management’s Ambit Biosciences Corp AMBI Stock Holding History

Eventide Asset Management’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-151,100
Closed -$1.04M – 107
2014
Q2 		$1.04M Buy
151,100
+20,000
+15% +$140K 0.14% 96
2014
Q1 		$1.2M Buy
131,100
+57,000
+77% +$605K 0.19% 89
2013
Q4 		$714K Buy
+74,100
New +$989K 0.22% 69

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Eventide Asset Management's AMBI Position: Q3 2014 in Review

Eventide Asset Management sold out of Ambit Biosciences Corp (AMBI) in Q3 2014, closing a stake of 151,100 shares — an estimated $1.04M sold.

Eventide Asset Management first reported a position in AMBI in Q4 2013 and held it in 3 quarters. The position peaked at $1.2M in Q1 2014. 49 funds tracked by Wall St. Rank hold AMBI as of Q3 2014.

  • Eventide Asset Management reported no remaining Ambit Biosciences Corp position as of Q3 2014 after selling out during the quarter.
  • Eventide Asset Management sold 151,100 Ambit Biosciences Corp shares in Q3 2014, an estimated $1.04M.
  • Eventide Asset Management first reported a position in Ambit Biosciences Corp in Q4 2013 and held it in 3 quarters.
  • Eventide Asset Management's Ambit Biosciences Corp position peaked at $1.2M in Q1 2014.
  • 49 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q3 2014.

Based on Eventide Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.